Vistagen Strengthens Its Neurology Focused Pipeline With Pherin Pharma Acquisition
- Vistagen Therapeutics Inc has agreed to acquire Pherin Pharmaceuticals Inc in an all-stock transaction of approximately 12.4 million shares.
- Pherin is a clinical-stage drug development company focused on discovering and developing investigational pherine compounds for neuropsychiatric and neuroendocrine conditions.
- Vistagen is gaining full ownership of intellectual property rights to its two most advanced drug candidates, PH94B, currently in Phase 3 development for social anxiety disorder (SAD) and Phase 2 development for adjustment disorder with anxiety (AjDA), and PH10, in clinical development for major depressive disorder (MDD).
- Vistagen will also expand its pipeline with three new early clinical-stage pherine product candidates: PH15 for cognition improvement, PH80 for migraine and hot flashes, and PH284 for appetite-related disorders.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.